Possible Role of Cannabis in the Management of Neuroinflammation in Patients with Post-COVID Condition

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(7), P. 3805 - 3805

Published: March 29, 2024

The post-COVID condition (PCC) is a pathology stemming from COVID-19, and studying its pathophysiology, diagnosis, treatment crucial. Neuroinflammation causes the most common manifestations of this disease including headaches, fatigue, insomnia, depression, anxiety, among others. Currently, there are no specific management proposals; however, given that inflammatory component involves cytokines free radicals, these conditions must be treated to reduce current symptoms provide neuroprotection risk long-term neurodegenerative disease. It has been shown cannabis compounds with immunomodulatory antioxidant functions in other pathologies. Therefore, exploring approach could viable therapeutic option for PCC, which purpose review. This review involved an exhaustive search specialized databases PubMed, PubChem, ProQuest, EBSCO, Scopus, Science Direct, Web Science, Clinical Trials. Phytocannabinoids, cannabidiol (CBD), cannabigerol (CBG), Delta-9-tetrahydrocannabinol (THC), exhibit significant antioxidative anti-inflammatory properties have effective neuroinflammatory conditions. These promising adjuvants PCC alone or combination antioxidants therapies. presents challenges neurological health, neuroinflammation oxidative stress play central roles pathogenesis. Antioxidant therapy cannabinoid-based approaches represent areas research mitigating adverse effects, but further studies needed.

Language: Английский

---

Efficacy of Vitamin D Replacement Therapy on 28 Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After COVID-19 Vaccination

Nutrition, Journal Year: 2025, Volume and Issue: 134, P. 112718 - 112718

Published: Feb. 19, 2025

Prolonged symptoms have been reported following both COVID-19 infection and vaccination, with some cases leading to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Of 80 patients presenting our hospital postvaccination syndrome, 28 met the diagnostic criteria for ME/CFS. We conducted a retrospective study on these patients. measured serum 25-hydroxyvitamin D levels in who developed ME/CFS after vaccination between August 2022 February 2024. Vitamin replacement therapy included dietary counseling, sun exposure recommendations, oral vitamin supplementation. evaluated changes blood symptom improvement. At initial visit, 27 of diagnosed had insufficient or deficient (16 ± 4 ng/mL, mean SD). Following therapy, we observed an increase (28 5 ng/mL) associated decrease (from 10.3 2.1 3.3 2.0). Notably, 23 (82%) no longer therapy. Among symptoms, sleep problems showed most improvement (71%), followed by autonomic (68%). For developing levels, appropriate under medical guidance may lead symptomatic relief. are preparing randomized controlled trial evaluate efficacy individuals deficiency vaccination.

Language: Английский

---

Vitamin D status in children with COVID-19: does it affect the development of long COVID and its symptoms?

Frontiers in Pediatrics, Journal Year: 2025, Volume and Issue: 13

Published: Feb. 14, 2025

Long COVID is characterized by diverse symptoms persisting after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Given the immunomodulatory and neuroprotective properties of vitamin D, understanding its role in long growing interest. This study aimed to determine D status children with COVID-19 assess impact on clinical course disease development. A prospective cohort included hospitalized confirmed COVID-19, aged 1 month 18 years, diagnosed between September 2022 March 2024. Serum 25-hydroxyvitamin (25(OH)D) concentrations were measured upon hospital admission, follow-up was done identify symptoms. In total, 162 patients examined. Vitamin deficiency determined 8.0%, insufficiency 25.3%, optimal levels 66.7% COVID-19. deficiency/insufficiency observed 73% over 6 years 21.6% under age. Comorbid conditions 1.4 times more frequent insufficiency, undernutrition obesity playing most significant roles (p = 0.0023, p 0.0245, respectively). 25(OH)D concentration depends severity 0.0405) had a longer stay (4 vs. 3 days, 0.0197). The affected median neutrophils, lymphocytes, their ratio, prothrombin time, fibrinogen levels, frequency increased immunoglobulins M E levels. Among 134 who agreed follow up, 56 (41.8%) experienced symptoms, while 78 (58.2%) recovered fully. frequently 0.0331). odds developing 2.2 higher 0.0346) compared those Children often exhibited neurological (80% 41.9%, 0.0040) musculoskeletal (16% 0%, 0.0208). depended affect influenced duration hospitalization. There an risk deficiency/insufficiency, development associated established.

Language: Английский

---

Proteomics Reveals That Vitamin D Deficiency Leads to Immunoglobulin Abnormalities and Immune Dysregulation in Patients with Post-COVID-19 Condition

Journal of Proteome Research, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 20, 2025

Vitamin D (VD) levels are closely related to the occurrence of post-COVID-19 conditions (PCCs), but specific mechanism is still unclear. Here, a total 50 PCC patient serum samples were divided into VD sufficient group (VD ≥ 30 ng/mL), insufficient (20 ng/mL ≤ < and deficiency 20 ng/mL) then subjected proteomic analysis. We identified 15 differential abundance proteins (DAPs) between groups, including 5 immunoglobulin (JCHAJN, IGHV4–28, GHV4–34, IGHM, IGLV2–11), which significantly negatively correlated with in patients. These DAPs primarily enriched immune-related pathways such as TNF signaling pathway B cell receptor pathway. Compared group, resulted 4 being upregulated 8 downregulated. The declined IGLV1–47 levels. Albumin (ALB) was center protein–protein interaction (PPI) network map all In conclusion, insufficiency/deficiency leads abnormalities heavy, light, J chains, resulting syndrome. supplementation may be potential therapeutic strategy alleviate symptoms PCC.

Language: Английский

---

Systematic review of optimizing brain-targeted vitamin D delivery: Novel approaches to enhance mental illness therapeutics

Brain Research, Journal Year: 2025, Volume and Issue: 1858, P. 149656 - 149656

Published: April 24, 2025

Language: Английский

---

Association of Vitamin D Supplementation with Glutathione Peroxidase (GPx) Activity, Interleukine-6 (IL-6) Levels, and Anxiety and Depression Scores in Patients with Post-COVID-19 Condition

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(10), P. 4582 - 4582

Published: May 10, 2025

Coronavirus disease 2019 (COVID-19) presents with various symptoms, and some patients develop post-COVID-19 condition (PCC). Vitamin D has shown therapeutic potential in COVID-19 may offer benefits for PCC. The aim of this study was to evaluate the differences associated two supplementation strategies (bolus daily) on interleukin-6 (IL-6) levels, glutathione peroxidase (GPx) activity, clinical outcomes PCC patients, regardless whether target 25 (OH) levels reached ideal range. We conducted a self-controlled which 54 participants were supplemented vitamin D3 (n = 28 bolus n 26 2 months. Blood samples collected measure IL-6 GPx activity using spectrophotometric methods. Hospital Anxiety Depression Scale (HADS) used assess mental function. Both daily significantly increased decreased levels. Daily additionally significant reduction anxiety depression scores. However, neither regimen improvements cough, dyspnea, or fatigue. These findings suggest association between antioxidant neuropsychiatric parameters PCC, possibly mediated by its immunomodulatory properties. Further placebo-controlled trials are warranted determine these observed associations reflect causal relationships.

Language: Английский

---

The impact of social distancing measures (quarantine) policy on tertiary education and medical consultations in China during the COVID-19 pandemic

Frontiers in Public Health, Journal Year: 2024, Volume and Issue: 12

Published: March 5, 2024

The impact of social distancing measures (quarantine) policy on tertiary education and medical consultations in China during the COVID-19 pandemic

Language: Английский

---

A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: June 12, 2024

Abstract There have been 774,075,242 cases of COVID-19 and 7,012,986 deaths worldwide as January 2024. In the early stages pandemic, there was an urgent need to reduce severity disease prevent for hospitalization avoid stress on healthcare systems worldwide. The repurposing drugs clinical deterioration patients trialed in many studies using different drugs. Fluvoxamine (an SSRI sigma-1 receptor agonist) initially identified potentially provide beneficial effects COVID-19-infected patients, preventing hospitalization. Fourteen carried out date, with seven those being randomized placebo-controlled studies. This systematic review meta-analysis covers literature from outbreak SARS-CoV-2 late 2019 until Search terms related fluvoxamine, such its trade names chemical names, along words COVID-19, coronavirus, were used databases including PubMed, Google Scholar, Scopus, ClinicalTrials.gov database NIH, identify trials subsequent analysis. Clinical death data extracted these where available meta-analysis. A total 7153 studied across 14 (both open-label double-blind placebo-controlled). 681 3553 (19.17%) standard care group 255 3600 (7.08%) fluvoxamine-treated experienced deterioration. estimated average log odds ratio 1.087 (95% CI 0.200 1.973), which differed significantly zero (z = 2.402, p 0.016). resulted a 0.359 0.1111 0.5294), 3.103, 0.002). results this study fluvoxamine effective deterioration, subgrouping analysis suggests that earlier treatment dose 200 mg or above provides best outcomes. We hope outcomes can help design future into respiratory viral infections improve

Language: Английский

---

Effects of an 8‐week high‐dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post‐COVID syndrome: A randomized controlled trial

Psychiatry and Clinical Neurosciences, Journal Year: 2024, Volume and Issue: unknown

Published: July 28, 2024

Aim This study evaluated the effectiveness of high‐dose vitamin D supplementation in alleviating fatigue and neuropsychiatric symptoms post‐COVID syndrome. Methods In an 8‐week, double‐blind, randomized, placebo‐controlled trial, 80 patients with or were enrolled. Participants randomly assigned to receive either 60,000 IU weekly ( n = 40) a placebo for 8 weeks. Clinical outcomes assessed using 11‐item Chalder Fatigue Scale (CFQ‐11); 21‐item Depression, Anxiety, Stress (DASS‐21); Pittsburgh Sleep Quality Index (PSQI); Addenbrooke's Cognitive Examination III (ACE); Trail Making Test A B (TMT‐A TMT‐B). Baseline 8‐week measurements inflammatory markers, including interleukin 6 (IL‐6) C‐reactive protein (CRP), also collected. Results Significant improvements found group CFQ (coefficient −3.5, P 0.024), DASS‐anxiety (−2.0, 0.011), ACE (2.1, 0.012). No significant differences observed PSQI, DASS‐depression, TMT, IL‐6, CRP levels. The incidence adverse events was comparable between groups, no serious reported. Conclusion High‐dose may benefit syndrome by reducing fatigue, anxiety, improving cognitive symptoms, minimal side effects.

Language: Английский

---

No association between genetically predicted vitamin D levels and Parkinson’s disease

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(11), P. e0313631 - e0313631

Published: Nov. 15, 2024

Background Parkinson’s disease (PD) is a neurodegenerative disorder, primarily characterized by motor impairments. Vitamin D has several regulatory functions in nerve cell survival and gene expression via its receptors. Although research shown that vitamin deficiency prevalent among PD patients, the causal link to risk remains unclear. This study aims investigate relationship between using bidirectional two-sample Mendelian randomization (MR) analysis method. Methods applied MR explore PD. We selected statistically significant single nucleotide polymorphisms (SNPs) related 25-hydroxyvitamin (25(OH)D) as instrumental variables (IVs), ensuring no association with known confounders. The used GWAS data from over 1.2 million Europeans across four major published datasets, elucidating genetic correlation levels Results identified 148 SNPs associated 25(OH)D. After adjustment for confounding-related SNPs, 131 remained analysis. Data three cohorts revealed 25(OH)D IVW method ( P cohort1 = 0.365, cohort2 0.525, cohort3 0.117). reverse indicated insufficient evidence of causing decreased 0.776). Conclusion first use results indicate are not significantly causally at level. Therefore, future studies should exercise caution when investigating risk. While direct exists PD, this does preclude potential biomarker diagnosis. Furthermore, larger-scale longitudinal necessary evaluate diagnostic predictive value

Language: Английский

---